Patents by Inventor Bryan D. LEMON

Bryan D. LEMON has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MESOTHELIN BINDING PROTEINS
    Publication number: 20240100157
    Abstract: Disclosed herein are MSLN binding proteins with improved binding affinities and improved ability to mediate T cell dependent killing of cancer cells expressing mesothelin. Pharmaceutical compositions comprising the binding proteins disclosed herein and methods of using such formulations are further provided.
    Type: Application
    Filed: March 15, 2023
    Publication date: March 28, 2024
    Inventors: Holger WESCHE, Bryan D. LEMON, Richard J. AUSTIN, Robert B. DUBRIDGE
  • COMBINATION THERAPY WITH IMMUNE CELL ENGAGING PROTEINS AND IMMUNOMODULATORS
    Publication number: 20240084035
    Abstract: Provided herein are combinations or compositions comprising immunomodulators and immune cell engaging proteins. Also provided herein are methods of use thereof, such as methods of treatment by administering the combinations or compositions comprising immunomodulators and immune cell engaging proteins to a subject. The method may be used to treat a cancer in the subject.
    Type: Application
    Filed: August 28, 2023
    Publication date: March 14, 2024
    Inventors: Mary Ellen MOLLOY, Che-Leung LAW, Richard J. AUSTIN, Bryan D. LEMON, Holger WESCHE, Wade H. AARON
  • SINGLE DOMAIN SERUM ALBUMIN BINDING PROTEIN
    Publication number: 20230257451
    Abstract: Disclosed herein are single domain serum albumins binding proteins with improved thermal stability, binding affinities, and robust aggregation profiles. Also described are multispecific binding proteins comprising a single domain serum albumin binding protein according to the instant disclosure. Pharmaceutical compositions comprising the binding proteins disclosed herein and methods of using such formulations are provided.
    Type: Application
    Filed: September 19, 2022
    Publication date: August 17, 2023
    Inventors: Robert B. DUBRIDGE, Bryan D. LEMON, Richard J. AUSTIN, Luke EVNIN, Jeanmarie GUENOT
  • Mesothelin binding proteins
    Patent number: 11607453
    Abstract: Disclosed herein are MSLN binding proteins with improved binding affinities and improved ability to mediate T cell dependent killing of cancer cells expressing mesothelin. Pharmaceutical compositions comprising the binding proteins disclosed herein and methods of using such formulations are further provided.
    Type: Grant
    Filed: January 27, 2020
    Date of Patent: March 21, 2023
    Assignee: HARPOON THERAPEUTICS, INC.
    Inventors: Holger Wesche, Bryan D. Lemon, Richard J. Austin, Robert B. Dubridge
  • Single domain serum albumin binding protein
    Patent number: 11453716
    Abstract: Disclosed herein are single domain serum albumins binding proteins with improved thermal stability, binding affinities, and robust aggregation profiles. Also described are multispecific binding proteins comprising a single domain serum albumin binding protein according to the instant disclosure. Pharmaceutical compositions comprising the binding proteins disclosed herein and methods of using such formulations are provided.
    Type: Grant
    Filed: October 16, 2018
    Date of Patent: September 27, 2022
    Assignee: HARPOON THERAPEUTICS, INC.
    Inventors: Robert B. Dubridge, Bryan D. Lemon, Richard J. Austin, Luke Evnin, Jeanmarie Guenot
  • TRISPECIFIC PROTEINS AND METHODS OF USE
    Publication number: 20220112297
    Abstract: Provided herein are B cell maturation agent (BCMA) targeting trispecific proteins comprising a domain binding to CD3, a half-life extension domain, and a domain binding to BCMA. Also provided are pharmaceutical compositions thereof, as well as nucleic acids, recombinant expression vectors and host cells for making such BCMA targeting trispecific proteins. Also disclosed are methods of using the disclosed BCMA targeting trispecific proteins in the prevention, and/or treatment diseases, conditions and disorders.
    Type: Application
    Filed: September 14, 2021
    Publication date: April 14, 2022
    Inventors: Holger WESCHE, Bryan D. LEMON, Richard J. AUSTIN
  • CONDITIONALLY ACTIVE RECEPTORS
    Publication number: 20220054544
    Abstract: Disclosed herein are conditionally active receptors which comprise a target antigen binding domain and a binding moiety. Each binding moiety comprises non-CDR loops for masking the binding of a target antigen binding domain to its target. The receptors are activated upon cleavage of the cleavable linkers. Pharmaceutical compositions comprising cells comprising the conditionally active receptors disclosed herein and methods of using such formulations are further provided.
    Type: Application
    Filed: May 14, 2019
    Publication date: February 24, 2022
    Inventors: Shuoyen Jack LIN, Richard J. AUSTIN, Bryan D. LEMON, Kevin WRIGHT, Holger WESCHE
  • Trispecific proteins and methods of use
    Patent number: 11136403
    Abstract: Provided herein are B cell maturation agent (BCMA) targeting trispecific proteins comprising a domain binding to CD3, a half-life extension domain, and a domain binding to BCMA. Also provided are pharmaceutical compositions thereof, as well as nucleic acids, recombinant expression vectors and host cells for making such BCMA targeting trispecific proteins. Also disclosed are methods of using the disclosed BCMA targeting trispecific proteins in the prevention, and/or treatment diseases, conditions and disorders.
    Type: Grant
    Filed: October 12, 2018
    Date of Patent: October 5, 2021
    Assignee: HARPOON THERAPEUTICS, INC.
    Inventors: Holger Wesche, Bryan D. Lemon, Richard J. Austin
  • BINDING MOIETY FOR CONDITIONAL ACTIVATION OF IMMUNOGLOBULIN MOLECULES
    Publication number: 20210292421
    Abstract: Disclosed herein are binding moieties that comprise non-CDR loops for masking the binding of a binding molecule to its target and CDRs for binding bulk serum proteins. Conditionally active target binding proteins that contain the binding moieties are also provided. Pharmaceutical compositions comprising the binding proteins disclosed herein and methods of using such formulations are further provided.
    Type: Application
    Filed: May 14, 2019
    Publication date: September 23, 2021
    Inventors: Shuoyen Jack LIN, Richard J. AUSTIN, Bryan D. LEMON, Kathryn KWANT, Sony S. ROCHA, Holger WESCHE
  • DUAL BINDING MOIETY
    Publication number: 20210284728
    Abstract: Disclosed herein is a dual binding moiety that comprises non-CDR loops for masking the binding of a domain, such as a target antigen binding domain to its target, by steric occlusion and specific masking, and CDRs for binding bulk serum proteins. Pharmaceutical compositions comprising the dual binding moiety disclosed herein and methods of using such compositions are further provided.
    Type: Application
    Filed: May 14, 2019
    Publication date: September 16, 2021
    Inventors: Shuoyen Jack LIN, Richard J. AUSTIN, Bryan D. LEMON, Holger WESCHE
  • CONDITIONALLY ACTIVATED BINDING PROTEIN COMPRISING A STERICALLY OCCLUDED TARGET BINDING DOMAIN
    Publication number: 20210269530
    Abstract: Disclosed herein is a conditionally active target binding protein that contains a first binding domain that binds to a bulk serum protein and sterically occludes binding of a second binding domain to its target. Pharmaceutical compositions comprising the conditionally active binding proteins disclosed herein and methods of using such compositions are further provided.
    Type: Application
    Filed: May 14, 2019
    Publication date: September 2, 2021
    Applicant: Harpoon Therapeutics, Inc.
    Inventors: Shuoyen Jack LIN, Richard J. AUSTIN, Bryan D. LEMON, Holger WESCHE
  • Compositions and methods for TCR reprogramming using fusion proteins
    Patent number: 11085021
    Abstract: Provided herein are T-cell receptor (TCR) fusion proteins (TFPs), T-cells engineered to express one or more TFPs, and methods of use thereof for the treatment of diseases, including cancer.
    Type: Grant
    Filed: August 10, 2020
    Date of Patent: August 10, 2021
    Assignee: TCR2 THERAPEUTICS INC.
    Inventors: Patrick Baeuerle, Gregory Sieczkiewicz, Robert Hofmeister, Holger Wesche, Bryan D. Lemon, Richard J. Austin, Robert B. Dubridge
  • B CELL MATURATION ANTIGEN BINDING PROTEINS
    Publication number: 20210171649
    Abstract: Disclosed herein are B cell maturation antigen binding proteins with improved binding affinities and improved ability to mediate killing of cancer cells expressing B cell maturation antigen (BCMA). Pharmaceutical compositions comprising the binding proteins disclosed herein and methods of treatment of a cancer or a metastasis thereof using such formulations are further provided.
    Type: Application
    Filed: January 15, 2021
    Publication date: June 10, 2021
    Inventors: Holger WESCHE, Bryan D. LEMON, Richard J. AUSTIN
  • PROSTATE SPECIFIC MEMBRANE ANTIGEN BINDING PROTEIN
    Publication number: 20210100902
    Abstract: Disclosed are PSMA binding proteins with improved binding affinities, and robust aggregation profiles. Also described are multispecific binding proteins comprising a PSMA binding protein according to the instant disclosure. Pharmaceutical compositions comprising the binding proteins disclosed and methods of using such formulations are further provided.
    Type: Application
    Filed: September 23, 2020
    Publication date: April 8, 2021
    Inventors: Robert DUBRIDGE, Pui SETO, Patrick BAEUERLE, Jeanmarie GUENOT, Holger WESCHE, Bryan D. LEMON, Richard J. AUSTIN
  • PSMA Targeting Trispecific Proteins and Methods of Use
    Publication number: 20210095047
    Abstract: Provided herein are prostate specific membrane antigen (PSMA) targeting trispecific proteins comprising a domain binding to CD3, a half-life extension domain, and a domain binding to PSMA. Also provided are pharmaceutical compositions thereof, as well as nucleic acids, recombinant expression vectors and host cells for making such PSMA targeting trispecific proteins. Also disclosed are methods of using the disclosed PSMA targeting trispecific proteins in the prevention, and/or treatment diseases, conditions and disorders.
    Type: Application
    Filed: October 16, 2020
    Publication date: April 1, 2021
    Inventors: Patrick BAEUERLE, Jeanmarie GUENOT, Holger WESCHE, Robert B. DUBRIDGE, Bryan D. LEMON, Richard J. AUSTIN, Pui SETO
  • B cell maturation antigen binding proteins
    Patent number: 10927180
    Abstract: Disclosed herein are B cell maturation antigen binding proteins with improved binding affinities and improved ability to mediate killing of cancer cells expressing B cell maturation antigen (BCMA). Pharmaceutical compositions comprising the binding proteins disclosed herein and methods of treatment of a cancer or a metastasis thereof using such formulations are further provided.
    Type: Grant
    Filed: October 12, 2018
    Date of Patent: February 23, 2021
    Assignee: HARPOON THERAPEUTICS, INC.
    Inventors: Holger Wesche, Bryan D. Lemon, Richard J. Austin
  • Prostate specific membrane antigen binding protein
    Patent number: 10849973
    Abstract: Disclosed herein are PSMA binding proteins with improved binding affinities, and robust aggregation profiles. Also described are multispecific binding proteins comprising a PSMA binding protein according to the instant disclosure. Pharmaceutical compositions comprising the binding proteins disclosed herein and methods of using such formulations are further provided.
    Type: Grant
    Filed: November 22, 2017
    Date of Patent: December 1, 2020
    Assignee: HARPOON THERAPEUTICS, INC.
    Inventors: Robert Dubridge, Pui Seto, Patrick Baeuerle, Jeanmarie Guenot, Holger Wesche, Bryan D. Lemon, Richard J. Austin
  • PSMA targeting trispecific proteins and methods of use
    Patent number: 10844134
    Abstract: Provided herein are prostate specific membrane antigen (PSMA) targeting trispecific proteins comprising a domain binding to CD3, a half-life extension domain, and a domain binding to PSMA. Also provided are pharmaceutical compositions thereof, as well as nucleic acids, recombinant expression vectors and host cells for making such PSMA targeting trispecific proteins. Also disclosed are methods of using the disclosed PSMA targeting trispecific proteins in the prevention, and/or treatment diseases, conditions and disorders.
    Type: Grant
    Filed: November 22, 2017
    Date of Patent: November 24, 2020
    Assignee: HARPOON THERAPEUTICS, INC.
    Inventors: Patrick Baeuerle, Jeanmarie Guenot, Holger Wesche, Robert B. Dubridge, Bryan D. Lemon, Richard J. Austin, Pui Seto
  • MESOTHELIN BINDING PROTEINS
    Publication number: 20200289646
    Abstract: Disclosed herein are MSLN binding proteins with improved binding affinities and improved ability to mediate T cell dependent killing of cancer cells expressing mesothelin. Pharmaceutical compositions comprising the binding proteins disclosed herein and methods of using such formulations are further provided.
    Type: Application
    Filed: January 27, 2020
    Publication date: September 17, 2020
    Inventors: Holger WESCHE, Bryan D. LEMON, Richard J. AUSTIN, Robert B. DUBRIDGE
  • MSLN TARGETING TRISPECIFIC PROTEINS AND METHODS OF USE
    Publication number: 20200270362
    Abstract: Provided herein are mesothelin (MSLN) targeting trispecific proteins comprising a domain binding to CD3, a half-life extension domain, and a domain binding to MSLN. Also provided are pharmaceutical compositions thereof, as well as nucleic acids, recombinant expression vectors and host cells for making such MSLN targeting trispecific proteins. Also disclosed are methods of using the disclosed MSLN targeting trispecific proteins in the prevention, and/or treatment of diseases, conditions and disorders.
    Type: Application
    Filed: February 26, 2020
    Publication date: August 27, 2020
    Inventors: Holger WESCHE, Bryan D. LEMON, Richard J. AUSTIN, Robert B. DUBRIDGE